Katherine Terracina, MD, & Prajakta P. Masurkar, PhD |
In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.
Incoming Arthritis & Rheumatology Editor-in-Chief Dr. S. Louis Bridges Jr., MD, PhD, discusses his path to rheumatology and outlines his vision for the journal.
The bill also enhances the state’s service cancelable loan program to help address critical shortages in the healthcare workforce. Much of the language draws from model policy previously developed by the ACR.
In visits to Congress members and staff, more than 120 ACR/ARP members and patients urged action to improve patient access to quality treatment. The meetings included discussions about the importance of research funding, ensuring adequate Medicare reimbursement, protecting Medicaid, and making PBMs more transparent and accountable. It’s not too late to amplify their message.
Three bills centering reintroduced in the 119th Congress would ease educational debt burden, increase placement access for visa holders and support the mental health of current healthcare workers.
Disease detection, access to care and remote patient monitoring are just a few areas in which AI is expected to aid rheumatology, but there will still be room for the human touch.
Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR |
Guest columnists Dr. Daniel Solomon & Dr. Andrew Concoff discuss the potential of technology, such as mobile health apps, to enhance remote care & improve access for underserved patients.
The Medicare Patient Access and Practice Stabilization Act of 2025 would fully offset the harmful 2.8% cut in the MPFS and include an additional 2% payment update to physician services furnished after April 1.
As state legislatures begin to convene their sessions in 2025, several key issues related to rheumatology are expected to take center stage, including drug costs, utilization management, telehealth and copay accumulators.
Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR |
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…